ArticleIranian journal of pharmaceutical research : IJPR
miR-146a-Enriched Mesenchymal Stem Cell-Derived Extracellular Vesicles Prolong Corneal Allograft Survival by Modulating Local and Systemic Immune Responses.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Corneal allograft rejection remains a leading cause of graft failure. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) may provide new options for modulating the immune response to allografts. Objectives: This study aimed to determine whether miR-146a-enriched EVs could prolong corneal allograft survival by modulating local and systemic immune responses. Methods: After corneal allografting from C57BL/6 to BALB/c mice, recipients received subconjunctival injections of PBS, miR-NC-EVs, or miR-146a-EVs isolated from human umbilical cord mesenchymal stem cells (hUCSCs). Local inflammatory and regulatory factors in ocular tissues were assessed using quantitative real-time polymerase chain reaction (qRT-PCR) to quantify the expression of interleukin-1 receptor-associated kinase 1 (IRAK1), TNF receptor-associated factor 6 (TRAF6), tumor necrosis factor (TNF)-α, and forkhead box protein 3 (Foxp3). Systemic cytokine profiles were assessed in recipient sera using enzyme-linked immunosorbent assay (ELISA) to measure interferon (IFN)-γ, interleukin (IL)-17, IL-10, and transforming growth factor (TGF)-β. Results: Clinical rejection scores were markedly reduced, with significant improvements in opacity, edema, and neovascularization. RT-PCR analysis of corneal tissue showed miR-146a overexpression, downregulation of IRAK1 and TRAF6, a significant reduction in TNF-α mRNA, and increased Foxp3 expression. ELISA analysis of systemic IFN-γ and IL-17 showed that treatment with miR-146a-EVs resulted in lower systemic IFN-γ and IL-17 levels and significantly higher levels of the anti-inflammatory cytokines, IL-10 and TGF-β. Conclusions: This study identifies miR-146a-EVs as a novel cell-free therapy that effectively prolongs corneal transplant survival. The treatment exerts dual immunomodulatory effects by regulating local inflammatory pathways and shifting systemic cytokine profiles toward an anti-inflammatory state, thereby offering a targeted strategy to prevent transplant rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.